SCHEMBL1506461

SCHEMBL1506461

O=C(Cl)[C@H]1CC[C@@H](C(=O)Cl)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 5/20 0.36
CHRNA3 P32297 5/20 0.36
CHRNA4 P43681 5/20 0.36
CHRNB4 P30926 3/20 0.36
CHRNA7 P36544 2/20 0.36
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
CHRNB3 Q05901 2/20 0.35
CHRNA6 Q15825 2/20 0.35
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ACE P12821 1/20 0.32
PLG P00747 1/20 0.32
PLAT P00750 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
AKR1C3 P42330 1/20 0.31
AKR1C1 Q04828 1/20 0.31
GABRP O00591 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4279 1.00
SCHEMBL1060400 1.00 CHRNB2 (0.36) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL890380 1.00 CHRNB2 (0.36) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
Hydrochloric Acid SCHEMBL1880027 0.96
Bicarbonate SCHEMBL27911841 0.93 LMNA (0.35) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL1087909 0.93 CHRNB2 (0.33) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL21391917 0.90 CES2 (0.43) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL2153805 0.90 CHRNB2 (0.37) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL13044828 0.90 CHRNB2 (0.37) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
Methylene Chloride SCHEMBL28166563 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179243-A1 MAIN CHAIN POLYMER, OPTICAL FILM, METHOD FOR PRODUCING MAIN CHAIN POLYMER, METHOD FOR PRODUCING OPTICAL FILM, AND MULTILAYER FILM TOSOH CORPORATION (JP) 2025-06-05 US disclosed
EP-4455128-A1 MAIN CHAIN POLYMER, OPTICAL FILM, METHOD FOR PRODUCING MAIN CHAIN POLYMER, METHOD FOR PRODUCING OPTICAL FILM, AND MULTILAYER FILM Tosoh Corporation (JP) 2024-10-30 EP disclosed
WO-2023120638-A1 MAIN CHAIN POLYMER, OPTICAL FILM, METHOD FOR PRODUCING MAIN CHAIN POLYMER, METHOD FOR PRODUCING OPTICAL FILM, AND MULTILAYER FILM 東ソー株式会社 2023-06-29 WO disclosed
CN-112512589-A Dimeric immunomodulatory compounds against CEREBLON-based mechanisms H·李·莫菲特癌症中心研究有限公司 2021-03-16 CN disclosed
EP-3214064-B1 METHOD FOR PREPARING 1,4-CYCLOHEXANEDICARBOXYLIC ACID DICHLORIDE TORAY FINECHEMICALS CO LTD (JP) 2019-10-09 EP disclosed
US-20190016662-A1 METHOD OF PRODUCING ACID HALIDE SOLUTION AND METHOD OF PRODUCING MONOESTER COMPOUND ZEON CORPORATION (JP) 2019-01-17 US disclosed
EP-3214064-A1 METHOD FOR PREPARING 1,4-CYCLOHEXANEDICARBOXYLIC ACID DICHLORIDE Toray Fine Chemicals Co., Ltd. (JP) 2017-09-06 EP disclosed
US-20150133663-A1 NOVEL SYNTHESIS METHOD GE HEALTHCARE LIMITED (GB) 2015-05-14 US disclosed
US-20150083657-A1 MEMBRANE AND METHOD FOR MAKING THE SAME GENERAL ELETRIC COMPANY (US) 2015-03-26 US disclosed
US-20140140928-A1 5HT1A ANTAGONIST USEFUL FOR IN VIVO IMAGING GE HEALTHCARE LIMITED (GB) 2014-05-22 US disclosed
US-8616380-B2 Reverse osmosis composite membranes for boron removal GENERAL ELECTRIC COMPANY (US) 2013-12-31 US disclosed
US-8580341-B2 Method of making composite membrane GENERAL ELECTRIC COMPANY (US) 2013-11-12 US disclosed
US-20120292249-A1 COMPOSITE MEMBRANE AND METHOD OF MAKING GENERAL ELECTRIC COMPANY (US) 2012-11-22 US disclosed
US-20120255909-A1 REVERSE OSMOSIS COMPOSITE MEMBRANES FOR BORON REMOVAL GENERAL ELECTRIC COMPANY (US) 2012-10-11 US disclosed
EP-2473261-A2 REVERSE OSMOSIS COMPOSITE MEMBRANES FOR BORON REMOVAL General Electric Company (US) 2012-07-11 EP disclosed
US-20110049055-A1 REVERSE OSMOSIS COMPOSITE MEMBRANES FOR BORON REMOVAL GENERAL ELECTRIC COMPANY (US) 2011-03-03 US disclosed
WO-2011025607-A2 REVERSE OSMOSIS COMPOSITE MEMBRANES FOR BORON REMOVAL GENERAL ELECTRIC COMPANY (US) 2011-03-03 WO disclosed
WO-2010135033-A1 COMPOSITE MEMBRANE AND METHOD OF MAKING GENERAL ELECTRIC COMPANY (US) 2010-11-25 WO disclosed
US-20100297429-A1 COMPOSITE MEMBRANE AND METHOD OF MAKING GENERAL ELECTRIC COMPANY (US) 2010-11-25 US disclosed
US-4734486-A Polyamide comprising fluorinated xylyene moieties ICI AMERICAS INC. (US) 1988-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179243-A1 MAIN CHAIN POLYMER, OPTICAL FILM, METHOD FOR PRODUCING MAIN CHAIN POLYMER, METHOD FOR PRODUCING OPTICAL FILM, AND MULTILAYER FILM C9, RNF4, F12 CHRNB2 2698/4885CHRNA3 1471/4885CHRNA4 1693/4885
US-20150133663-A1 NOVEL SYNTHESIS METHOD HTR1A, HTR5A, TPH1 CHRNB2 138/4885CHRNA3 115/4885CHRNA4 110/4885
US-20190016662-A1 METHOD OF PRODUCING ACID HALIDE SOLUTION AND METHOD OF PRODUCING MONOESTER COMPOUND HACL2, LIPA, HDHD5 CHRNB2 4790/4885CHRNA3 4625/4885CHRNA4 4632/4885
US-20140140928-A1 5HT1A ANTAGONIST USEFUL FOR IN VIVO IMAGING HTR1A, HTR1E, HTR5A CHRNB2 243/4885CHRNA3 200/4885CHRNA4 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.